Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study

BACKGROUND: Effective prophylactic therapies have not been established for hepatocellular carcinoma recurrence. Peretinoin represents one novel option for patients with hepatitis C virus-related hepatocellular carcinoma (HCV-HCC), and it was tested in a multicenter, randomized, double-blind, placebo...

Descripción completa

Detalles Bibliográficos
Autores principales: Okita, Kiwamu, Izumi, Namiki, Matsui, Osamu, Tanaka, Katsuaki, Kaneko, Shuichi, Moriwaki, Hisataka, Ikeda, Kenji, Osaki, Yukio, Numata, Kazushi, Nakachi, Kohei, Kokudo, Norihiro, Imanaka, Kazuho, Nishiguchi, Shuhei, Okusaka, Takuji, Nishigaki, Yoichi, Shiomi, Susumu, Kudo, Masatoshi, Ido, Kenichi, Karino, Yoshiyasu, Hayashi, Norio, Ohashi, Yasuo, Makuuchi, Masatoshi, Kumada, Hiromitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2014
Materias:
Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318984/
https://www.ncbi.nlm.nih.gov/pubmed/24728665
http://dx.doi.org/10.1007/s00535-014-0956-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318984/
https://www.ncbi.nlm.nih.gov/pubmed/24728665
http://dx.doi.org/10.1007/s00535-014-0956-9

Ejemplares similares